June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Positive charged nanoemulsion enhanced cyclosporine penetrate into cornea after ocular topical application
Author Affiliations & Notes
  • Junjie Zhang
    Dpt of Pharmaceutical Science, Henan Eye Institute, Henan Eye Hospital, Zhengzhou, China
  • Liya Wang
    Dpt of Pharmaceutical Science, Henan Eye Institute, Henan Eye Hospital, Zhengzhou, China
  • Tianyang Zhou
    Dpt of Pharmaceutical Science, Henan Eye Institute, Henan Eye Hospital, Zhengzhou, China
  • Jijun He
    Dpt of Pharmaceutical Science, Henan Eye Institute, Henan Eye Hospital, Zhengzhou, China
  • Huiyun Xia
    Dpt of Pharmaceutical Science, Henan Eye Institute, Henan Eye Hospital, Zhengzhou, China
  • Hongmin Zhang
    Dpt of Pharmaceutical Science, Henan Eye Institute, Henan Eye Hospital, Zhengzhou, China
  • Footnotes
    Commercial Relationships Junjie Zhang, None; Liya Wang, None; Tianyang Zhou, None; Jijun He, None; Huiyun Xia, None; Hongmin Zhang, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4694. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Junjie Zhang, Liya Wang, Tianyang Zhou, Jijun He, Huiyun Xia, Hongmin Zhang; Positive charged nanoemulsion enhanced cyclosporine penetrate into cornea after ocular topical application. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4694. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Cyclosporine (CsA) is an immunosuppressive agent that has shown a strong immunosuppressive effect in a variety of animal models of transplantation and experimental autoimmune uveitis and uveoretinitis after systemic adminstration. However, it has limited ocular therapeutic effects due to its poor permeability across ocular biological barriers while topical application. The purpose of this study is to develop positive charged nanoemulsion for enhancing the permeability of CsA across ocular biological barriers to treat uveitis after ocular topical application.

Methods: A series of positive charged nanoemulsions were prepared.. The size and zeta potential of the nanogels are studied by Malvin laser particle size analyzer. The release kinetics of CsA from the nanoemulsion were measured and calculated using bulk-equilibrium reverse dialysis bag technique. Ocular irritation test was performed in Japan White rabbits. The ocular distribution and pharmacokinetics of the CsA levels in the cornea, sclera, conjunctiva, aqueous humor, vitreous and whole blood were assessed after ocular single dose and loading dose topical application, resptively.

Results: Laser particle size analyzer measurement demonstrate that the sizes of the nanoemulsions are around 29-51 nm at room temperature, and the zeta potential are +15-31mV. The accumulative release of CsA from the nanoemulsions were more than 80% within 2 hours. Ocular pharmacokinetics of the nanogels strongly depend on the and charge characteristics of the nanoemulsions.

Conclusions: These findings indicate that positive charge nanoemulsion may be a promising vehicle for topical use of CSA to treat ocular immune-mediated diseases.

Keywords: 489 cyclosporine • 607 nanotechnology • 483 cornea: storage  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×